• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

行业指南:用于输血或进一步制造的人血及血液成分的化学、制造与控制以及机构描述信息的提交,以及FDA 356h表格“人用新药、生物制品或抗生素药物上市申请”的填写;发布情况。美国卫生与公众服务部食品药品监督管理局。通知。

"Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and for the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use;'" availability. Food and Drug Administration, HHS. Notice.

出版信息

Fed Regist. 1999 May 10;64(89):25049-50.

PMID:10558535
Abstract

The Food and Drug Administration (FDA) is announcing the availability of a document entitled "Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use.'" This guidance document is intended to assist applicants in the preparation of the content and format of the chemistry, manufacturing, and controls (CMC) section and the establishment description section of a biologics license application (BLA), revised Form FDA 356h, for human blood and blood components intended for transfusion or for further manufacture. In addition, this guidance document provides assistance for the completion of the BLA. This action is part of FDA's continuing effort to achieve the objectives of the President's "Reinventing Government" initiatives and the Food and Drug Administration Modernization Act of 1997 (Modernization Act), to reduce unnecessary burdens for industry without diminishing public health protection.

摘要

美国食品药品监督管理局(FDA)宣布可获取一份题为“行业指南:用于提交供输血或进一步制造的人血及血液成分的化学、制造与控制以及机构描述信息,以及填写FDA 356h表格‘人用新药、生物制品或抗生素药物上市申请’”的文件。本指南文件旨在协助申请人准备用于输血或进一步制造的人血及血液成分的生物制品许可申请(BLA)(修订后的FDA 356h表格)的化学、制造与控制(CMC)部分以及机构描述部分的内容和格式。此外,本指南文件还为完成BLA申请提供帮助。此行动是FDA持续努力的一部分,以实现总统“重塑政府”倡议和1997年《食品药品管理局现代化法案》(《现代化法案》)的目标,在不削弱公共卫生保护的情况下减轻行业不必要的负担。

相似文献

1
"Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and for the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use;'" availability. Food and Drug Administration, HHS. Notice.行业指南:用于输血或进一步制造的人血及血液成分的化学、制造与控制以及机构描述信息的提交,以及FDA 356h表格“人用新药、生物制品或抗生素药物上市申请”的填写;发布情况。美国卫生与公众服务部食品药品监督管理局。通知。
Fed Regist. 1999 May 10;64(89):25049-50.
2
"Guidance for industry: content and format of chemistry, manufacturing and controls information and establishment description information for a biological in vitro diagnostic product;" availability. Food and Drug Administration, HHS. Notice.工业指南:生物体外诊断产品的化学、制造和控制信息以及机构描述信息的内容和格式;可用性。美国卫生与公众服务部食品药品监督管理局。通知。
Fed Regist. 1999 Mar 8;64(44):11023-4.
3
"Guidance for Industry: On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test"; availability. Food and Drug Administration, HHS. Notice.
Fed Regist. 1999 Apr 23;64(78):20006-7.
4
Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license--FDA. Proposed rule.《公共卫生服务法》第351条规定的生物制品;生物制品许可的实施;取消机构许可和产品许可——美国食品药品监督管理局。拟议规则。
Fed Regist. 1998 Jul 31;63(147):40858-71.
5
Draft guidance for industry; exports and imports under the FDA Export Reform and Enhancement Act of 1996--FDA. Notice.行业指南草案;根据1996年《美国食品药品监督管理局出口改革与强化法案》进行的进出口——美国食品药品监督管理局。通知。
Fed Regist. 1998 Jun 12;63(113):32219-34.
6
International Conference on Harmonisation; guidance on electronic common technical document specification; availability. Notice.国际协调会议;电子通用技术文档规范指南;可用性。通知。
Fed Regist. 2003 Apr 2;68(63):16060-1.
7
Guidance for industry: donor screening for antibodies to HTLV-II; availability--FDA. Notice.行业指南:人嗜T淋巴细胞病毒II型抗体供体筛查;可获取性——美国食品药品监督管理局。通知。
Fed Regist. 1998 Sep 29;63(188):51942-3.
8
Revised precautionary measures to reduce the possible transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products; guidance document; availability--FDA. Notice.修订后的预防措施以减少克雅氏病(CJD)通过血液及血液制品的可能传播;指导文件;可获取性——美国食品药品监督管理局。通知。
Fed Regist. 1997 Sep 23;62(184):49694-5.
9
International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice.国际协调会议;S9 抗癌药物非临床评价指南;可获取性。通知。
Fed Regist. 2010 Mar 8;75(44):10487-8.
10
International Conference on Harmonisation; revised guidance on Q3B(R) Impurities in New Drug Products; Availability. Notice.国际协调会议;《新药产品中的杂质Q3B(R)》修订指南;获取情况。通知。
Fed Regist. 2003 Nov 14;68(220):64628-9.

引用本文的文献

1
A general framework for developing computable clinical phenotype algorithms.开发可计算临床表型算法的一般框架。
J Am Med Inform Assoc. 2024 Aug 1;31(8):1785-1796. doi: 10.1093/jamia/ocae121.
2
Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance.对肿瘤细胞内在的以及细胞间CLPTM1L/CRR9介导的化疗耐药性进行靶向生物抑制。
NPJ Precis Oncol. 2021 Mar 2;5(1):16. doi: 10.1038/s41698-021-00152-9.
3
Global immunoglobulin supply: steaming towards the iceberg?
全球免疫球蛋白供应:驶向冰山?
Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):557-564. doi: 10.1097/ACI.0000000000000696.